DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has received notification of U.S. Patent Office approval for technology to which Corgenix holds exclusive worldwide licensing rights outside of Japan. The technology is incorporated in the Company’s AtherOx™ product group, a next-generation technology to identify individuals at risk for developing atherosclerotic cardiovascular disease.
